Durvalumab, with or without tremelimumab, plus...

The Lancet Oncology 2020 / 12

Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial

Goldman, Jonathan W, Dvorkin, Mikhail, Chen, Yuanbin, Reinmuth, Niels, Hotta, Katsuyuki, Trukhin, Dmytro, Statsenko, Galina, Hochmair, Maximilian J, Özgüroğlu, Mustafa, Ji, Jun Ho, Garassino, Marin
How much do you like this book?
What’s the quality of the file?
Download the book for quality assessment
What’s the quality of the downloaded files?
Journal:
The Lancet Oncology
DOI:
10.1016/S1470-2045(20)30539-8
Date:
December, 2020
File:
PDF, 1.76 MB
2020
Conversion to is in progress
Conversion to is failed